BIO-FD&C Co.,Ltd.
Financials
Valuation Metrics
BIO-FD&C Co.,Ltd.'s Market Cap is ₩701B. At end of 2025 it was ₩1374B. Ranked #1489 of 2,436 in KR market (top 61%), #854 of 1,649 on KOSDAQ (top 52%), #163 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.09B KRW | KR#1,489/2,436 Sec#163/234 |
| Revenue | 18.85B KRW | KR#2,151/2,436 Sec#157/234 |
| Net Income | 6.20B KRW | KR#1,056/2,436 Sec#70/234 |
| Total Assets | 74.51B KRW | KR#1,947/2,436 Sec#163/234 |
| Net Assets | 70.96B KRW | KR#1,634/2,436 Sec#140/234 |
| Employees | 76 | KR#1,814/2,436 Sec#154/234 |
| Value | ||
| P/E | 11.31x | KR#786/2,436 Sec#44/234 |
| P/B | 0.99x | KR#1,478/2,436 Sec#96/234 |
| P/S | 3.72x | KR#2,066/2,436 Sec#133/234 |
| EV/EBITDA | 10.01x | KR#603/2,436 Sec#27/234 |
| FCF Yield | 8.99% | KR#659/2,436 Sec#30/234 |
| Profitability | ||
| ROE | 8.73% | KR#616/2,436 Sec#37/234 |
| ROA | 8.32% | KR#303/2,436 Sec#22/234 |
| Op. Margin | 30.97% | KR#48/2,436 Sec#12/234 |
| Revenue Growth | -7.54% | KR#1,795/2,436 Sec#167/234 |
| Earnings Growth | -28.74% | KR#1,101/2,436 Sec#69/234 |
| Financial Health | ||
| Debt Ratio | 105.00% | KR#357/2,436 Sec#49/234 |
| Total Debt | 100.0M KRW | KR#2,029/2,436 Sec#194/234 |
| FCF | 6.30B KRW | KR#841/2,436 Sec#56/234 |
| Cash | 11.73B KRW | KR#1,581/2,436 Sec#120/234 |
| Current Ratio | 17.86x | KR#33/2,436 Sec#13/234 |
| Net Debt/EBITDA | -1.99x | KR#299/2,436 Sec#17/234 |
| Performance | ||
| 1Y Return | -55.47% | KR#2,173/2,436 Sec#205/234 |
| 1M Return | -6.28% | KR#1,498/2,436 Sec#150/234 |
| From 52W High | -60.20% | KR#1,720/2,436 Sec#144/234 |
| 1Y MDD | -64.76% | KR#1,680/2,436 Sec#141/234 |
| Trading | ||
| Volume | 14,687 shares | KR#1,993/2,436 Sec#200/234 |
| Foreign Own. | 11.73% | KR#423/2,436 Sec#39/234 |
| Per Share | ||
| EPS | 713 KRW | KR#763/2,436 Sec#56/234 |
| BPS | 8,320 KRW | KR#1,054/2,436 Sec#72/234 |
Company Info
Established in 2005, the company conducts research, development, and production of active and pharmacological substances based on its plant cell platform technology. With 18 years of accumulated expertise, it boasts the world's largest plant cell library and has established a Plant Cell Banking system for cryopreserving over 120 species. Utilizing the world's first SMART-RC² new technology with high-frequency waveform application, the company's mass culture process supplies various clients, realizing steady sales growth. BIOFD&C is headquartered in Yeonsu-gu, Incheon.